(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Dealbreaker on MSN16h
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private EquityCarlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...
RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...
A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.
Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback